John Radford

29.6k citations

377 papers · 15.7k indexed · 5 hit papers · h-index 65

Impact in

Pathology and Forensic Medicine top 0.02%
- Lymphoma Diagnosis and Treatment
Oncology top 0.1%
- CAR-T cell therapy research
- Viral-associated cancers and disorders

Papers in

Pathology and Forensic Medicine 248
- Lymphoma Diagnosis and Treatment 245
Genetics 91
- Chronic Lymphocytic Leukemia Research 90

Co-authors: Peter Johnson D. Crowther A. Z. S. Rohatiner Ruth Pettengell David Cunningham David C. Linch Barry W. Hancock Pier Luigi Zinzani
Journals: Blood (84 papers)Journal of Clinical Oncology (59 papers)Annals of Oncology (24 papers)British Journal of Cancer (21 papers)British Journal of Haematology (20 papers)
Partner nations: United Kingdom United States Italy

In The Last Decade

John Radford

362 papers receiving 15.2k citations

Hit Papers

5 papers align trajectories log scale

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial 2021 · 264 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 The Lancet Oncology
2017 Journal of Clinical Oncology
2015 New England Journal of Medicine
2013 The Lancet
1998 Blood

Peers

Countries citing papers authored by John Radford

Since Specialization

Citations

This map shows the geographic impact of John Radford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Radford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Radford more than expected).

Fields of papers citing papers by John Radford

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Radford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Radford. The network helps show where John Radford may publish in the future.

Co-authorship network

The 25 scholars most cited alongside John Radford, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John Radford Line = papers co-authored together John Radford links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Effect of Exogenous Ketones as an Adjunct to Low-Calorie Diet on Metabolic Markers Nutrients ·Sudad Alhadad, Genevieve Parker, A. Giacosa, Joshua Raveendran, Haroon Asghar, Klaus Kramer, Amy C. Reynolds, E. Evans, John Radford, Frank Davis, Paul R. Reynolds, R. Ryley Parrish, Benjamin T. Bikman	2025	0
2	Involved Field Radiotherapy Versus No Further Treatment in Patients with Newly Diagnosed Stage 1A or 2A Hodgkin Lymphoma and a ‘Negative’ PET Scan after 3 Cycles ABVD. Survival and Cause of Death after a Median of 16 Years Follow-up in the UK RAPID Trial Blood ·John Radford, Tosin Anthony Oniyelu, Edvin Hornbrinck, Ruth Pettengell, Peter Johnson, Peter Hoskin, Tim Illidge, Nicholas Counsell	2024	0
3	Pilot study of lung cancer screening for survivors of Hodgkin lymphoma Haematologica ·Zhang Tingting, Philip Crosbie, Christopher J. Armitage, Ben Taylor, Ataalah Mohmmed Al Qataan, Животова Светлана Сергеевна, John Radford, Kim Linton	2023	1
4	Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study Blood Advances ·Juan Pablo Alderuccio, Weiyun Z. Ai, John Radford, Melhem Solh, Kirit M. Ardeshna, Matthew A. Lunning, Brian Hess, Pier Luigi Zinzani, Anastasios Stathis, Carmelo Carlo‐Stella, Mehdi Hamadani, Brad S. Kahl, David Ungar, M Kmera-Muszyńska, Eric Yu, Tracey Heath, Paolo F. Caimi	2022	1
5	Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project Blood ·Ranjana H. Advani, Tetiana Skrypets, Monica Civallero, Michael A. Spinner, Martina Manni, Won-Seog Kim, Andrei R. Shustov, Steven M. Horwitz, Felicitas Hitz, María Elena Cabrera, Iván Dlouhy, José Vassallo, Stefano Pileri, Giorgio Inghirami, Silvia Montoto, Umberto Vitolo, John Radford, Julie M. Vose, Massimo Federico	2021	60
6	Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium Blood ·Angie Mae Rodday, Susan K. Parsons, 老段, Ranjana H. Advani, Massimo Federico, Jonathan W. Friedberg, Andrea Gallamini, David Hodgson, Peter Hoskin, Martin Hutchings, Peter Johnson, Kara M. Kelly, Brian K. Link, John Radford, Pier Luigi Zinzani, James R. Cerhan, John Raemaekers, Andrew M. Evens	2020	3
7	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma Blood ·Mehdi Hamadani, John Radford, Carmelo Carlo‐Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl	2020	122
8	Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma Leukemia ·Franck Morschhauser, Martin J.S. Dyer, Harriet S. Walter, Alexey V. Danilov, Loïc Ysebaert, Daniel J. Hodson, Chris Fegan, Simon Rule, John Radford, Guillaume Cartron, Krimo Bouabdallah, Andrew Davies, Stephen E. Spurgeon, Nishanthan Rajakumaraswamy, Biao Li, Rita Humeniuk, Xi Huang, Pankaj Bhargava, Juliane M. Jürgensmeier, Gilles Salles	2020	13
9	Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety Journal of Clinical Oncology ·Wolfgang Hiddemann, Anna Maria Barbui, Miguel Canales, Paul Cannell, Graham P. Collins, Jan Dürig, Roswitha Forstpointner, Michael Herold, Mark Hertzberg, Magdalena Klánová, John Radford, John F. Seymour, Kensei Tobinai, Judith Trotman, Αλέξανδρος Κόκκινος, Günter Fingerle‐Rowson, A. Holin, Tina Nielsen, Robert Marcus	2018	144
10	Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma Blood ·Mehdi Hamadani, Graham P. Collins, Felipe Samaniego, Alexander I. Spira, Andrew Davies, John Radford, Paolo Caimi, Tobias Menne, Joseph Boni, Hans G. Cruz, Jay Feingold, Shui He, Jens Wuerthner, Steven M. Horwitz	2018	35
11	Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma Journal of Clinical Oncology ·Robert Chen, Pier Luigi Zinzani, Michelle A. Fanale, Philippe Armand, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Yinghua Zhang, Alejandro D. Ricart, Arun Balakumaran, Craig H. Moskowitz, (unknown) Hit paper breakdown →	2017	694
12	Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma Journal of Clinical Oncology ·Franck Morschhauser, John Radford, Achiel Van Hoof, Umberto Vitolo, Pierre Soubeyran, Hervé Tilly, Peter C. Huijgens, Arne Kolstad, Francesco d’Amore, Marcos González, Mario Petrini, Catherine Sebban, Pier Luigi Zinzani, Marinus H. J. van Oers, Wim van Putten, A. Bischof-Delaloye, A. Z. S. Rohatiner, Gilles Salles, Jens Kuhlmann, Anton Hagenbeek	2008	314
13	Myeloablative therapy for recurrent Hodgkin lymphoma: Good success rates irrespective of previous treatments in the UKLG LY09 trial (ISRCTN97144519) ePrints Soton (University of Southampton) ·Н О Бажанов, Matthew R. Sydes, Bruno C. Hancock, M.H. Cullen, Sally Stenning, John Radford	2008	2
14	Changes in serological biomarkers (BM) of cell death during chemotherapy (CT) in patients with lymphoma Annals of Oncology ·Alastair Greystoke, Kim Linton, Tim Illidge, Ronald L. Cowan, Carly MacArthur, Thomas M. Ward, S.N. Stulov, Malcolm Ranson, Ameeka George, John Radford, Caroline Dive	2008	1
15	Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study Journal of Clinical Oncology ·Paul Lorigan, Jaap Verweij, Zsuzsa Pápai, Sjoerd Rodenhuis, Axel Le Cesne, Michael Leahy, John Radford, M. M. Van Glabbeke, Anne Kirkpatrick, Pancras C.W. Hogendoorn, Jean‐Yves Blay	2007	192
16	Response-adapted therapy using FDG-PET scanning after initial ABVD: the UK NCRI, Italian and Nordic trial in advanced Hodgkin lymphoma ePrints Soton (University of Southampton) ·Peter Johnson, Massimo Federico, Gunilla Enblad, Christopher Burton, Paul A. Smith, W. Qian, M. J. OʼDoherty, John Radford	2007	1
17	Chlamydia psittaci is variably associated with ocular MALT lymphoma in different geographical regions UCL Discovery (University College London) ·Estelle Chanudet, Peg Crowley-Nowick, Chris M. Bacon, AC Wotherspoon, H. K. Müller-Hermelink, Patrick Adam, Kulkarni Hrushikesh Bhujangrao, Rui-Li Wei, Е. С. Троицкая, Qiaoxing Wu, Renzo Ranaldi, Gaia Goteri, Stefano Pileri, Tomoyuki KARASAWA, Ruediger W. Knodt, John Radford, Pratiwi Hanjani Putri	2006	2
18	Predicting septic complications of chemotherapy: An analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis European Journal of Cancer ·John Radford, W. David J. Ryder, D. Dodwell, Heather Anderson, N. Thatcher	1993	45
19	VAPEC B: a weekly chemotherapy for high grade non-Hodgkin's lymphoma. Early results of a collaborative trial at two centres. UCL Discovery (University College London) ·John Radford, JS Whelan, D.P. Deakin, Mercedes Correa Campos, Lister Ta, D. Crowther	1990	1
20	Urinary 6-oxo prostaglandin F1 alpha in myocardial infarction. BMJ ·Б.Ж. Жаканбева, Yan Wang, R.G.G. Russell, John Radford, J. F. MARTIN	1983	4

About John Radford

John Radford is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, General Psychology and Neurology, having authored 377 papers that have together received 15.7k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (245 papers), Chronic Lymphocytic Leukemia Research (90 papers), Lung Cancer Treatments and Mutations (78 papers), Viral-associated cancers and disorders (54 papers), CNS Lymphoma Diagnosis and Treatment (43 papers), CAR-T cell therapy research (43 papers), Monoclonal and Polyclonal Antibodies Research (28 papers) and Cutaneous lymphoproliferative disorders research (15 papers). The work is most often cited by research in Pathology and Forensic Medicine (8.8k citations), Oncology (7.8k citations), Genetics (3.0k citations), Neurology (2.4k citations) and Reproductive Medicine (1.0k citations). John Radford has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Peter Johnson, D. Crowther, A. Z. S. Rohatiner, Ruth Pettengell, David Cunningham, David C. Linch, Barry W. Hancock, Pier Luigi Zinzani, Jean‐Yves Blay and Martin Harris. Their work appears in journals such as Blood, Journal of Clinical Oncology, Annals of Oncology, British Journal of Cancer and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact